Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
|Poll|January 3, 2014
Swollen Purple Toe
A 20-year-old woman presents in mid-winter with a mildly painful, swollen, and discolored left toe of a week’s duration. What cause do you suspect?
Advertisement
A 20-year-old woman presents in mid-winter with a mildly painful, swollen, and discolored left toe of a week’s duration. She had also noted several small pruritic lesions on the toes of both feet.
What cause do you suspect?
Advertisement
Related to this article
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
An EHR-integrated tool matched manual CKD and cardiovascular risk assessments in 60 patients and showed promise for improving risk-based kidney care in primary care.
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
Advertisement
Advertisement
Trending on Patient Care Online
1
What the CLARITY Study Means for Counseling on Long-Acting HIV PrEP
2
CagriSema Cuts Weight Up to 27% Across Menopause Stages: TMS 2026
3
New Study Finds Low Initiation, Persistence With Menopause Hormone Therapy
4
Elinzanetant for Menopause-Related VMS: Onset of Relief and Adverse Effects
5